Trial Profile

A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PIT 565 (Primary) ; PIT 565 (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals

Most Recent Events

12 Dec 2023 Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition
22 Nov 2023 Planned End Date changed from 27 Feb 2026 to 5 Jun 2028.
22 Nov 2023 Planned primary completion date changed from 28 Feb 2025 to 7 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com